🍽️ diosmin,(polyphenol)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Venous Health: Diosmin is commonly used in the treatment of venous disorders, such as chronic venous insufficiency (CVI) and hemorrhoids. It works by improving venous tone and reducing venous congestion, thereby alleviating symptoms such as leg pain, swelling, and discomfort. Diosmin may also help to strengthen blood vessel walls and improve microcirculation, promoting better venous function and reducing the risk of complications associated with venous insufficiency.

  2. Vascular Protection: Diosmin has been shown to have protective effects on the vascular system. It helps to reduce inflammation and oxidative stress in blood vessels, which can help to prevent or slow the progression of vascular diseases such as atherosclerosis (hardening of the arteries) and thrombosis (blood clot formation). Diosmin may also help to improve endothelial function and vascular tone, contributing to overall cardiovascular health.

  3. Anti-inflammatory Effects: Diosmin exhibits anti-inflammatory properties, meaning it can reduce inflammation in the body. Chronic inflammation is associated with the development and progression of various diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. By reducing inflammation, diosmin may help to alleviate symptoms and slow the progression of these diseases.

  4. Antioxidant Effects: Diosmin acts as an antioxidant, meaning it can neutralize harmful free radicals in the body. Free radicals are unstable molecules that can damage cells and contribute to aging and various diseases. By scavenging free radicals, diosmin helps to protect cells from oxidative stress and reduce the risk of oxidative damage to tissues throughout the body.

  5. Lymphatic Health: Diosmin may also have benefits for lymphatic health. It helps to improve lymphatic drainage and reduce lymphatic congestion, which can help to alleviate symptoms such as swelling and discomfort associated with lymphedema (accumulation of lymph fluid). Diosmin may also help to improve immune function and reduce the risk of infections by supporting lymphatic circulation and drainage.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations    |     πŸ“ Dosage Seen

Data Contradictions β€” Limits of Certainity

Impacted of diosmin,(polyphenol) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by diosmin,(polyphenol)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Blautia genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Lacticaseibacillus genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Blautia obeum species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Bacteroides ovatus species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of diosmin,(polyphenol) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.2 -0.2
ADHD 1.3 0.1 12
Age-Related Macular Degeneration and Glaucoma 0.4 0.4
Allergic Rhinitis (Hay Fever) 0.9 0.8 0.13
Allergies 2.2 0.5 3.4
Allergy to milk products 0.2 0.2 0
Alopecia (Hair Loss) 0.8 0.8
Alzheimer's disease 0.9 2.6 -1.89
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.5 0.1 4
Ankylosing spondylitis 1.4 0.9 0.56
Anorexia Nervosa 0.9 -0.9
Antiphospholipid syndrome (APS) 0.2 0.2
Asthma 0.4 0.7 -0.75
Atherosclerosis 0.4 0.5 -0.25
Atrial fibrillation 1.2 0.5 1.4
Autism 3.9 2.5 0.56
Barrett esophagus cancer 0.2 0.1 1
Bipolar Disorder 0.2 0.6 -2
Brain Trauma 0.4 0.5 -0.25
Carcinoma 1.4 1.2 0.17
Celiac Disease 0.5 1.6 -2.2
Cerebral Palsy 0.5 0.9 -0.8
Chronic Fatigue Syndrome 2.6 1.9 0.37
Chronic Kidney Disease 1.6 0.6 1.67
Chronic Lyme 0.5 -0.5
Chronic Obstructive Pulmonary Disease (COPD) 0.5 0.3 0.67
Chronic Urticaria (Hives) 0.3 0.3 0
Coagulation / Micro clot triggering bacteria 0.1 0.8 -7
Colorectal Cancer 0.7 0.4 0.75
Constipation 0.2 0.7 -2.5
Coronary artery disease 0.9 0.7 0.29
COVID-19 4.3 4.4 -0.02
Crohn's Disease 2.6 1.6 0.63
cystic fibrosis 0.6 -0.6
deep vein thrombosis 0.4 -0.4
Depression 4.3 3.2 0.34
Dermatomyositis 0.1 0.2 -1
Eczema 0.9 0.3 2
Endometriosis 0.9 0.3 2
Eosinophilic Esophagitis 0.2 -0.2
Epilepsy 1.2 1 0.2
Fibromyalgia 1 0.5 1
Functional constipation / chronic idiopathic constipation 0.8 2 -1.5
gallstone disease (gsd) 0.7 0.5 0.4
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 1 -4
Generalized anxiety disorder 1.1 0.7 0.57
Glioblastoma 0.1 -0.1
Graves' disease 0.6 1.1 -0.83
Halitosis 0.4 0.1 3
Hashimoto's thyroiditis 1.9 0.3 5.33
Hidradenitis Suppurativa 0.1 0.2 -1
Histamine Issues,Mast Cell Issue, DAO Insufficiency 1.1 0.8 0.38
hypercholesterolemia (High Cholesterol) 0.1 0.1 0
hyperglycemia 1 -1
Hyperlipidemia (High Blood Fats) 0.5 0.3 0.67
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 0.7 2.4 -2.43
Hypothyroidism 0.7 -0.7
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 1.2 -1.2
Inflammatory Bowel Disease 1.7 2.3 -0.35
Insomnia 0.7 0.5 0.4
Intelligence 0.1 -0.1
Intracranial aneurysms 0.6 0.3 1
Irritable Bowel Syndrome 1.7 1.1 0.55
Liver Cirrhosis 1.6 1.1 0.45
Long COVID 3.6 3.6 0
Low bone mineral density 0.3 -0.3
Lung Cancer 0.6 0.7 -0.17
ME/CFS with IBS 0.5 1.4 -1.8
ME/CFS without IBS 1.3 0.6 1.17
Menopause 0.8 0.8
Metabolic Syndrome 3.5 2.9 0.21
Mood Disorders 5.2 3.3 0.58
multiple chemical sensitivity [MCS] 0.4 0.4 0
Multiple Sclerosis 1.9 0.7 1.71
Multiple system atrophy (MSA) 1 0.6 0.67
Neuropathy (all types) 0.6 0.6
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1 2.5 -1.5
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 5 1.9 1.63
obsessive-compulsive disorder 1.6 2.5 -0.56
Osteoarthritis 1.1 1.1
Osteoporosis 0.5 0.7 -0.4
pancreatic cancer 0.2 0.2
Parkinson's Disease 0.8 1.1 -0.38
Polycystic ovary syndrome 0.6 0.6 0
Postural orthostatic tachycardia syndrome 0.2 -0.2
Premenstrual dysphoric disorder 0.9 0.9
primary biliary cholangitis 0.1 0.3 -2
Psoriasis 1.7 0.7 1.43
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3 1.3 1.31
Rosacea 0.8 0.3 1.67
Schizophrenia 2 0.9 1.22
Sjögren syndrome 1.4 1.1 0.27
Sleep Apnea 0.6 1 -0.67
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.4 -3
Stress / posttraumatic stress disorder 0.8 1.3 -0.63
Systemic Lupus Erythematosus 1.8 1 0.8
Tic Disorder 0.1 0.6 -5
Tourette syndrome 0.1 0.2 -1
Type 1 Diabetes 1 0.7 0.43
Type 2 Diabetes 3.5 1.7 1.06
Ulcerative colitis 1.2 1.2 0
Unhealthy Ageing 2.5 0.6 3.17

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.